These results conclusively demonstrated that farrerol exerted a protective effect against hepatic steatosis and injury through its targeted modulation of the PTPN1‐INSR‐PI3K‐AKT signalling pathway (Figure 6). The gene discussed is PTPN1; the disease is fatty liver disease.